TIDMMDC
RNS Number : 7987T
Mediclinic International plc
22 July 2020
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(" Mediclinic ", or the "Company " or the "Group")
22 July 2020
DIRECTORATE CHANGES
APPOINTMENT OF STEVE WEINER AS AN INDEPENDENT NON-EXECUTIVE
DIRECTOR
Mediclinic, a leading diversified international private
healthcare services group, announces the appointment of Steve
Weiner as an independent non-executive director and a member of the
Audit and Risk and Clinical Performance and Sustainability
committees with effect from 22 July 2020.
Mr Weiner is currently a non-executive director of Guys' and St
Thomas' NHS Foundation Trust, one of the largest NHS Foundation
Trusts in the UK, where he chairs the Transformation and Major
Programmes Committee; is a member of the Strategy and Partnerships
committee; and a member of the Audit Committee, which he chaired
from 2014 to 2018. He is also a non-executive director and a member
of the Finance and Commercial Committee of King's College Hospital
NHS Foundation Trust, one of London's largest and busiest teaching
hospitals. Prior to this, Mr Weiner spent most of his career in
finance with the international consumer goods group Unilever, most
recently as Group Controller responsible for performance
management, accounting, reporting and control. He was also a member
of Unilever's Global Finance Leadership Team, working closely with
the group's board and Audit Committee.
Dame Inga Beale, Chair Designate of Mediclinic, commented:
"The Board is delighted to welcome Steve as an independent
non-executive director of the Company, following a rigorous and
thorough search process. He brings significant healthcare and
international consumer goods experience in executive and
non-executive finance and business transformation leadership roles
in large, complex organisations in developed and developing
markets. I am sure he will be a great addition to our Board of
Directors."
Steve Weiner, independent non-executive director, commented:
"It gives me great pleasure to be joining the Board of Directors
at Mediclinic. I have been impressed with the way the Group
continues to adapt to the evolving healthcare landscape, creating
opportunities across the continuum of care for the benefit of
patients. I believe my broad expertise in the sector can support
the advancement of this and other key strategic goals in the
future."
Mr Weiner holds a Masters in Finance from Columbia University
and a Bachelor of Science in Management from Rutgers
University.
This announcement is made in accordance with the requirement of
LR 9.6.11. There are no disclosures required pursuant to paragraphs
(1) to (6) of LR 9.6.13 R of the United Kingdom Listing Authority's
Listing Rules in respect of this appointment.
CHANGES TO COMMITTEE MEMBERSHIPS
As announced on 24 July 2019, Dr Edwin Hertzog is retiring as a
non-executive director and Chair of Mediclinic at the conclusion of
the Company's 2020 Annual General Meeting, being held today and
will be succeeded by Dame Inga Beale. Dr Hertzog will receive no
remuneration payment or payment for loss of office in connection
with his retirement other than his usual director's fee for the
month of July 2020 and any expenses incurred in attending Board
meetings.
The Board has agreed to certain changes to the membership of its
committees reflecting Dr Hertzog's retirement and Mr Weiner's
appointment, as follows:
Audit and Risk Committee:
Mr Weiner will be appointed as an additional member of the Audit
and Risk Committee with effect from 22 July 2020.
Nomination Committee:
With effect from 22 July 2020, Dr Hertzog will step down as
Chair of the Nomination Committee and will be succeeded by Dame
Inga Beale.
Clinical Performance and Sustainability Committee:
With effect from 22 July 2020, Dr Hertzog will step down as a
member of the Clinical Performance and Sustainability Committee and
Mr Weiner will be appointed as a member of the Committee from that
date.
Investment Committee:
Dr Hertzog will step down as Chair and member of the Investment
Committee with effect from 22 July 2020 and the Nomination
Committee will consider the appointment of a new member to the
Committee in due course.
Remuneration Committee:
There are no changes to the composition of the Remuneration
Committee.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare
services group, established in South Africa in 1983, with divisions
in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
At 1 July 2020, Mediclinic comprised 76 hospitals, eight
sub-acute and specialised hospitals, 15 day case clinics and 18
outpatient clinics. Hirslanden operated 17 hospitals and three day
case clinics in Switzerland with more than 1 800 inpatient beds;
Mediclinic Southern Africa operations included 52 hospitals (three
of which in Namibia), eight sub-acute and specialised hospitals and
10 day case clinics (four of which operated by Intercare) across
South Africa, and more than 8 700 inpatient beds; and Mediclinic
Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the
UAE.
The Company's primary listing is on the London Stock Exchange
("LSE") in the United Kingdom, with secondary listings on the JSE
Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9548
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co
International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of
FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPPUCGMUPUGCP
(END) Dow Jones Newswires
July 22, 2020 10:30 ET (14:30 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024